Gilead Calls Forty Seven Buyout Complementary To Kite, Other IO Efforts
Executive Summary
Gilead will pay $4.9bn to acquire Forty Seven and its potential first-in-class anti-CD47 agent magrolimab. A fast-track development effort in myelodysplastic syndrome will be the initial focus for that asset.
You may also be interested in...
Gilead Buys Pipeline-In-A-Product With $21bn Immunomedics Deal
The company paid twice Immunomedics’ last closing stock price to access Trodelvy, approved for triple-negative breast cancer with potential in other solid tumors as monotherapy and in combinations.
$2bn AbbVie Deal Puts I-Mab On Global Immuno-Oncology Map
In another clear signal that China's innovative drug R&D is coming of age, most global rights to I-Mab's promising early-stage CD47 antibody have been picked up by AbbVie in a deal valued at close to $2bn.
Gilead Licenses Novel Immunotherapy From Jounce
Deal snapshot: Gilead’s latest significant cancer deal brings it a CCR8 binder, a novel preclinical immunotherapy, while Jounce finds a new deep-pocketed partner after the termination of its collaboration with Celgene.
Need a specific report? 1000+ reports available
Buy Reports